OS Therapies Incorporated entered into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026, establishing an at-the-market (ATM) equity offering program. Under this agreement, the company may offer and sell shares of its common stock from time to time up to an aggregate offering price of $75 million. The sales agent receives a commission equal to 3.0% of the gross proceeds, and the company agreed to reimburse legal fees not exceeding $100,000. Net proceeds are intended to fund clinical development activities, advance research programs, and potentially acquire complementary technologies or businesses. OS Therapies operates in the biotechnology industry, focusing on drug discovery and development.

OS Therapies Incorporated entered into a securities purchase agreement for an August Private Placement of senior secured convertible promissory notes with an aggregate subscription amount of up to $10,000,000. The company consummated the initial closing on August 10, 2026, issuing Notes in an aggregate principal amount of $5,405,405.42, along with common stock and warrants. This transaction included the automatic conversion of a previously issued $2,200,000 bridge convertible promissory note into new Notes and equity securities. The Notes bear 9.0% annual interest, mature nine months after funding, and are convertible at $2.05 per share. Warrants to purchase common stock were issued with an exercise price of $2.85 per share for the first tranche. Proceeds will fund clinical development, regulatory activities, working capital, and general corporate purposes. OS Therapies operates in the biotechnology industry, focusing on the discovery and development of novel therapies.

OS Therapies Inc. entered into a settlement agreement with Leonite Fund I, LP to resolve disputes regarding a prior $10 million secured convertible note financing. Under the terms of the settlement, OS Therapies agreed to pay Leonite $1.9 million in cash and issue 500,000 shares of common stock by August 7, 2026. This payment was funded on August 3, 2026, using proceeds from a new $2.2 million bridge convertible promissory note issued to an accredited investor on August 2, 2026. The settlement results in the cancellation of the original Leonite Note and warrants, while the bridge note matures on September 1, 2026, or converts into future equity offerings. OS Therapies Inc. operates in the veterinary pharmaceutical industry, developing treatments for animal health.

OS Therapies Inc terminated its At Market Issuance Sales Agreement with B. Riley Securities, Inc. and JonesTrading Institutional Services LLC effective July 28, 2026. The agreement allowed for the sale of up to $18 million in common stock; however, only 282,679 shares were sold for approximately $530,162 in gross proceeds before termination. Approximately $17.47 million remained unsold under the facility. No termination fees or payments were due by either party. OS Therapies Inc operates in the biotechnology industry and focuses on developing therapies for rare diseases.